Yoshikazu Inoue

TL;DR: In this paper, a guideline for idiopathic pulmonary fibrosis (IPF) based on evidence was proposed in order to promote evidence-based clinical practice and further improve the quality of medical treatment in the clinical setting.

TL;DR: Idiopathic pleuroparenchymal fibroelastosis is an acceptable entity among IIPs and not as rare as previously reported, and hypothesized that PPFE was not a rare disease entity.

TL;DR: This review article assesses the status of proposed biomarkers for chronic fibrosing lung diseases with a progressive phenotype in predicting disease risk or predisposition, diagnosis, prognosis and treatment response, and provides a direct comparison between idiopathic pulmonary fibrosis and other chronic fibrotic interstitial lung diseases.

TL;DR: The results suggest that change in CRPM is not a marker of response to nintedanib in patients with idiopathic pulmonary fibrosis, and rising concentrations of CRPM over 12 weeks were associated with disease progression.

TL;DR: Interstitial lung disease is still an adverse drug reaction of interest in this population, and these results, including ILD risk factors, give helpful information for treatment selection and monitoring.